Combination treatment induced higher calreticulin tumor exposure, increased frequency of tumor-infiltrating CD3+ T cells, and higher CD8+ T cell-to-Tregs ratio compared to IRE alone. Further, it reduced the tumor growth of both treated and non-treated tumors more than IRE alone. This evidence concerns the gene CALR and neoplasm.